# A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis

> **NCT01011309** · PHASE2 · COMPLETED · sponsor: **Access to Advanced Health Institute (AAHI)** · enrollment: 45 (actual)

## Conditions studied

- Cutaneous Leishmaniasis

## Interventions

- **BIOLOGICAL:** LEISH-F2 + MPL-SE
- **DRUG:** Sodium stibogluconate

## Key facts

- **NCT ID:** NCT01011309
- **Lead sponsor:** Access to Advanced Health Institute (AAHI)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2013-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011309, "A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01011309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*